Literature DB >> 1063125

Human deoxythymidine kinase. I. Purification and general properties of the cytoplasmic and mitochondrial isozymes derived from blast cells of acute myelocytic leukemia.

L S Lee, Y C Cheng.   

Abstract

Two forms of deoxythymidine kinase from blast cells of acute myelocytic leukemia were identified by electrophoresis. One was associated mainly with the cytoplasm and the other with mitochondria. Both isozymes were separated and purified by differential affinity column chromatography which resulted in 2416- and 1634-fold purification of the cytoplasmic and mitochondrial enzymes, respectively. Affinity gel was prepared by linkage through position 3' of deoxythymidine. Each enzyme had the same electrophoretic mobility in the purified state as it did in the enzyme derived from the corresponding subcellular fraction of the homogenate. Thymidine phosphorylase was not retarded by the affinity column. The purified cytoplasmic and mitochondrial deoxythymidine kinase had different molecular weights, sensitivities to inhibition by ammonium sulfate, activation energies for the reaction and divalent cation requirements. Adenosine, guanosine, and cytosine 3':5'-monophosphates, putrescine, spermine, and spermidine were neither activators nor inhibitors of either deoxythymidine kinase.

Entities:  

Mesh:

Substances:

Year:  1976        PMID: 1063125

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  47 in total

1.  Inhibition of replication of hepatitis B virus by cytallene in vitro.

Authors:  Y L Zhu; S B Pai; S H Liu; K L Grove; B C Jones; C Simons; J Zemlicka; Y C Cheng
Journal:  Antimicrob Agents Chemother       Date:  1997-08       Impact factor: 5.191

2.  Clinical isolate of herpes simplex virus type 2 that induces a thymidine kinase with altered substrate specificity.

Authors:  M N Ellis; P M Keller; J A Fyfe; J L Martin; J F Rooney; S E Straus; S N Lehrman; D W Barry
Journal:  Antimicrob Agents Chemother       Date:  1987-07       Impact factor: 5.191

3.  Synthesis and biological effects of 2'-fluoro-5-ethyl-1-beta-D-arabinofuranosyluracil.

Authors:  T C Chou; X B Kong; M P Fanucchi; Y C Cheng; K Takahashi; K A Watanabe; J J Fox
Journal:  Antimicrob Agents Chemother       Date:  1987-09       Impact factor: 5.191

4.  Selectivity of action of an antiherpetic agent, 9-(2-hydroxyethoxymethyl) guanine.

Authors:  G B Elion; P A Furman; J A Fyfe; P de Miranda; L Beauchamp; H J Schaeffer
Journal:  Proc Natl Acad Sci U S A       Date:  1977-12       Impact factor: 11.205

5.  Unique metabolism of a novel antiviral L-nucleoside analog, 2'-fluoro-5-methyl-beta-L-arabinofuranosyluracil: a substrate for both thymidine kinase and deoxycytidine kinase.

Authors:  S H Liu; K L Grove; Y C Cheng
Journal:  Antimicrob Agents Chemother       Date:  1998-04       Impact factor: 5.191

6.  Characterization of an Epstein-Barr virus-induced thymidine kinase.

Authors:  M de Turenne-Tessier; T Ooka; G de The; J Daillie
Journal:  J Virol       Date:  1986-03       Impact factor: 5.103

7.  G1 cyclin degradation: the PEST motif of yeast Cln2 is necessary, but not sufficient, for rapid protein turnover.

Authors:  S R Salama; K B Hendricks; J Thorner
Journal:  Mol Cell Biol       Date:  1994-12       Impact factor: 4.272

8.  Purification and biochemical characterization of deoxythymidine kinase of deoxythymidine kinase-deficient mouse 3T3 cells biochemically transformed by equine herpesvirus type 1.

Authors:  J J McGowan; G P Allen; G A Gentry
Journal:  Infect Immun       Date:  1979-08       Impact factor: 3.441

9.  Biochemical characterization of equine herpesvirus type 3-induced deoxythymidine kinase purified from lytically infected horse embryo dermal fibroblasts.

Authors:  J J McGowan; G P Allen; J M Barnett; G A Gentry
Journal:  J Virol       Date:  1980-05       Impact factor: 5.103

10.  Molecular cloning and cell cycle-specific regulation of a functional human thymidine kinase gene.

Authors:  H D Bradshaw
Journal:  Proc Natl Acad Sci U S A       Date:  1983-09       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.